Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Lexicon Pharmaceuticals (LXRX), Zogenix (ZGNX) and Dicerna Pharma (DRNA).
Lexicon Pharmaceuticals (LXRX)
Needham analyst Joseph Stringer maintained a Hold rating on Lexicon Pharmaceuticals today. The company’s shares closed last Thursday at $4.46.
According to TipRanks.com, Stringer has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.9% and a 12.5% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Phathom Pharmaceuticals, and Crispr Therapeutics AG.
Currently, the analyst consensus on Lexicon Pharmaceuticals is a Hold with an average price target of $7.00.
See today’s analyst top recommended stocks >>
Zogenix (ZGNX)
Needham analyst Serge Belanger maintained a Buy rating on Zogenix today and set a price target of $48.00. The company’s shares closed last Thursday at $17.53, close to its 52-week low of $16.73.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of 5.7% and a 46.7% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and KalVista Pharmaceuticals.
Zogenix has an analyst consensus of Strong Buy, with a price target consensus of $52.50, which is a 201.9% upside from current levels. In a report released today, Mizuho Securities also reiterated a Buy rating on the stock with a $55.00 price target.
Dicerna Pharma (DRNA)
In a report released today, Keay Nakae from Chardan Capital maintained a Buy rating on Dicerna Pharma, with a price target of $34.00. The company’s shares closed last Thursday at $26.67.
According to TipRanks.com, Nakae is a 5-star analyst with an average return of 24.0% and a 44.6% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Lineage Cell Therapeutics, and Arrowhead Pharmaceuticals.
Currently, the analyst consensus on Dicerna Pharma is a Strong Buy with an average price target of $41.83, representing a 49.4% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $40.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
